Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial.

"Duality of Interest. F.G.-P. has taken part in advisory panels for Insulcloud S.L., Sanofi, and Novo Nordisk; has received research support from Sanofi, Novo Nordisk, Boehringer Ingelheim, and EliLilly; and has acted as a speaker for Sanofi, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly. C.A. has received research support from Sanofi, Novo Nordisk, Boehringer Ingelheim, and Eli Lilly and has acted as a speaker for Sanofi, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, and Bristol-Myers Squibb. E.F.-R. has acted as a speaker for Novo Nordisk, Eli Lilly, and AstraZeneca. L.C. has acted as a speaker for Sanofi, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, and Eli Lilly. P.P. has received research support from Novo Nordisk and has acted as a speaker for Sanofi, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, and Eli Lilly. D.B. has received research support from and acted as a speaker for Sanofi, Novo Nordisk, Boehringer Ingelheim, and Eli Lilly. E.M.T. has received research support from Sanofi and Novo Nordisk and has acted as a speaker for Sanofi, Novo Nordisk, and Eli Lilly. No other potential conflicts of interest relevant to this article were reported."

"Funding. This study was funded by the European Commission (grant 739148) and Insulcloud, S.L., which provided the Insulclock devices and telemedicine system tested. Medical writing and statistical assistance were funded by the European Union Horizon 2020 (project identifier 674505)."